OR WAIT null SECS
Almac announced the results of a survey conducted by researchers at the Tufts Center for the Study of Drug Development.
Almac Group, a global provider of technology and services for the pharmaceutical and biotech industries announced the results of a survey conducted by researchers at the Tufts Center for the Study of Drug Development, which was backed by a grant from Almac. The survey found that sponsor and CRO companies are receptive to, and plan to increase their use of ePRO. The results revealed that the top benefits of ePRO adoption are increased data quality, patient compliance, and efficiency of data collection.
The results of the survey, http://www.almacgroup.com/wp-content/uploads/Tufts-CSDD-Study-of-ePRO-Usage-in-Clinical-Trials.pdf based on 22 responses from 18 companies, also show that the adoption rate of ePRO will continue to rise, as it is still a relatively new addition to clinical research programs. More than two-fifths (61%) of respondents indicated their companies began using ePRO in the last five years, while 11% have been using ePRO for more than 10 years. In examining future trends, more than three-quarters of respondents expected that there would be increasing ePRO usage for post-marketing trials for primary and secondary endpoints.
Read the full release here.